Abstract by Dean Slocum
Chemistry and Biochemistry
Pam Van Ry
An Innovative Treatment for Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) is a life-threatening form of interstitial lung disease with no cure. The average prognosis is 2-5 years and the cause is unknown. As the disease progresses, the interstitium of the lungs becomes scarred and limited in elasticity, eventually leading to death. It is believed that chronic, unknown lung injury events activate the TGFb pathway through the upstream activator avb6 integrin. We have tested a novel therapeutic that targets the avb6 integrin and find it effective in preserving lung function in the standard IPF mouse model that uses bleomycin to mimic lung fibrosis. FlexiVent machinery was used to measure lung mechanics and bronchoalveolar lavage fluid (BALF) was collected and analyzed. The lung mechanics data and the BALF profile of our bleomycin plus therapeutic-treated mice closely mimic results of non-treated mice as compared to mice treated with bleomycin alone. This suggests our therapeutic is a promising treatment for IPF.